Cohance Lifesciences Shares Tumble Following Managing Director's Resignation

Cohance Lifesciences , a prominent player in the pharmaceutical industry, experienced significant market turbulence on Wednesday as its shares plummeted following a major leadership change.

Leadership Transition

The company announced that Dr. V Prasada Raju has resigned from his position as Managing Director and Director, effective from the close of business hours on October 28. Dr. Raju cited personal priorities and a desire to continue his learning journey as reasons for his departure.

In response to this development, the Board of Directors has taken swift action to ensure continuity in leadership:

Resignation: Dr. V Prasada Raju (DIN: 07267366) steps down as Managing Director and Director.
New Appointment: Mr. Himanshu Agarwal (DIN: 06672915), the current Chief Financial Officer, has been appointed as an Additional Director and Whole-Time Director for a five-year term, subject to shareholder approval.

Market Reaction

The news of Dr. Raju's resignation had an immediate impact on Cohance Lifesciences' stock performance:

Metric	Value
Initial Price Drop	Up to 10%
Closing Price	₹804.80
Daily Decline	6.40%
Decline from 52-week High	28.00%
Year-to-Date Performance	-25.00%

The sharp decline in share price reflects investor concerns about the company's leadership transition and its potential impact on future performance.

Company's Response

Cohance Lifesciences has emphasized its commitment to a smooth transition. Dr. Raju will remain available to the company during the notice period to facilitate an orderly handover of his duties and responsibilities.

Mr. Himanshu Agarwal, who has been serving as the CFO, brings over 30 years of diverse financial experience to his new role. His appointment is seen as a move to maintain financial stability and strategic continuity within the organization.

Investor Communication

In light of these developments, Cohance Lifesciences has scheduled a conference call for investors and analysts on October 28 at 6:30 PM IST. This call aims to provide further clarity on the leadership changes and address any concerns from the investment community.

As Cohance Lifesciences navigates this transition, the market will be closely watching for signs of stability and continued growth under the new leadership structure. The company's ability to maintain its strategic direction and operational efficiency will be crucial in regaining investor confidence in the coming months.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-8.81%	-13.09%	-28.95%	-41.85%	-50.16%	+90.69%

Cohance Lifesciences Limited , a global technology-led CDMO and API+ organization, has announced significant changes in its leadership structure. The company's Board of Directors, in a meeting held on October 28, 2025, approved several key decisions that will reshape its top management.

Leadership Transition

Dr. V Prasada Raju has resigned from his position as Managing Director and Director of Cohance Lifesciences. His resignation will take effect from the close of business hours on October 28, 2025. Dr. Raju, in his resignation letter, cited personal priorities and a desire to continue his learning journey as reasons for his departure.

The Board has approved the appointment of Mr. Himanshu Agarwal, the company's current Chief Financial Officer, as an Additional Director. Mr. Agarwal will be designated as Whole-time Director and Chief Financial Officer, effective October 29, 2025, for a five-year term, subject to shareholder approval through a postal ballot process.

Key Details of the Transition

Aspect	Details
Outgoing Executive	Dr. V Prasada Raju
Position Vacated	Managing Director and Director
Effective Date of Resignation	Close of business hours, October 28, 2025
Incoming Executive	Mr. Himanshu Agarwal
New Designation	Whole-time Director and Chief Financial Officer
Effective Date of Appointment	October 29, 2025
Appointment Term	5 years (subject to shareholder approval)

Profile of the New Appointee

Mr. Himanshu Agarwal brings extensive experience to his new role. He is a finance professional with over 30 years of work experience across multiple countries and finance profiles. Mr. Agarwal has been associated with Cohance Lifesciences as CFO since January 2, 2024.

His prior experience includes roles at multinational companies such as ICI India, Huhtamaki, AkzoNobel India, and AstraZeneca Pharma. Notably, Mr. Agarwal has served as CFO and Whole-time Director at some of these organizations.